# A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors

> **NCT06006273** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 48 (estimated)

## Conditions studied

- Refractory Solid Tumors

## Interventions

- **DRUG:** Eribulin
- **DRUG:** Irinotecan
- **DRUG:** Temozolomide

## Key facts

- **NCT ID:** NCT06006273
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-08-16
- **Primary completion:** 2026-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06006273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06006273, "A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06006273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*